$-0.15 EPS Expected for Summit Therapeutics plc (SMMT)

November 11, 2018 - By Hannah Black

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.15 EPS on December, 5.They anticipate $0.05 EPS change or 25.00 % from last quarter’s $-0.2 EPS. After having $2.10 EPS previously, Summit Therapeutics plc’s analysts see -107.14 % EPS growth. The stock decreased 1.96% or $0.03 during the last trading session, reaching $1.5. About 28,981 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has declined 86.01% since November 11, 2017 and is downtrending. It has underperformed by 101.63% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 3 analysts covering Summit Therapeutics (NASDAQ:SMMT), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Summit Therapeutics had 3 analyst reports since June 27, 2018 according to SRatingsIntel. Janney Capital downgraded the shares of SMMT in report on Thursday, June 28 to “Neutral” rating. On Wednesday, June 27 the stock rating was downgraded by SunTrust to “Hold”. The company was downgraded on Wednesday, June 27 by Oppenheimer.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $26.25 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It has a 0.78 P/E ratio. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Globenewswire.com which released: “Award of Share Options” on October 22, 2018, also Globenewswire.com with their article: “Director/PDMR Shareholding” published on October 24, 2018, Globenewswire.com published: “New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group …” on October 17, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: Globenewswire.com and their article: “Detailed Research: Economic Perspectives on OUTFRONT Media, Limoneira, Papa John’s International, Everi …” published on November 09, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering” with publication date: November 08, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: